Goldman Sachs co-hosted investor launches of the 2021 Access to Medicine Index
On Tuesday 9 March 2021, Goldman Sachs and the Access to Medicine Foundation co-hosted the final of a series of investor launch events on the 2021 Access to Medicine Index. The three events brought together over 250 investors as well as company representatives from Europe, USA and Japan.
The Access to Medicine Index ranks 20 of the world’s largest pharma companies on how they manage material risks and opportunities related to access to medicine, including value drivers such as governance, compliance, R&D, pricing, management of intellectual property and product delivery.
Three events, three timezones
The virtual events provided institutional investors with the opportunity to dive into the findings of the new report, attend panel discussions on global health and investment trends and participate in 1-1 meetings with pharmaceutical companies to discuss past performance and future plans.
The three events each focused on companies from a specific geographic region and were co-hosted by the local team from Goldman Sachs.
Launch Event 1: Europe
Wednesday, 24 February 2021
- José Manuel Barroso (Chair, Gavi Board; former President of the European Commission and former Prime Minister of Portugal)
- Peter Sands (Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria)
- Richard Hatchett (Executive Director, CEPI)
- Moderated by Sharmin Mossavar-Rahmani (Head of Investment Strategy Group, Goldman Sachs)
- Alexandrea Robert (Head of Capital Markets, Sanofi)
- Diana Noble (Member of the Bank of England’s Court of Directors and Board Member of MedAccess)
- Franck Rizzoli (ESG Debt Financing EMEA, Goldman Sachs)
- Moderated by John Goldstein (Head of the Sustainable Finance Group, Goldman Sachs)
Launch event 2: USA
Thursday, 4 March 2021
9:00 AM EST
- Kelli Okuji-Wilson (Healthcare Analyst, SASB)
- Tachi Yamada (Venture Partner, Frazier Healthcare)
- Tom McPartland (CEO, ELMA Philanthropies)
- Moderated by Damiano de Felice (Director of Strategy, Access to Medicine Foundation)
Launch event 3: Japan
Tuesday, 9 March 2021
11:00 AM JST
- Isao Teshirogi, Ph.D. (President and CEO, Shionogi & Co., Ltd.)
- Shinichiro Hyogo (Chief Fund Manager, Mitsubishi UFJ Trust)
- Moderated by Akinori Ueda (Japan Pharmaceutical / Healthcare sector analyst, Goldman Sachs)
2021 Access to Medicine Index: latest analysis of pharma action
The Access to Medicine Foundation published the 7th Access to Medicine Index on 26 January 2021. The latest report shows what 20 of the world’s biggest pharmaceutical companies are doing to improve access to medicine for people living in 106 low- and middle-income countries.
The 2021 Index uses a framework of 33 metrics to assess the full range of company actions to improve access to medicine. It covers 82 diseases, conditions and pathogens. These include common killers, from HIV/AIDS, TB and malaria, to lower respiratory infections, diarrhoeal diseases, heart disease, dengue and others. People in low- and middle-income countries face more than 80% of the global burden of these diseases.
The 2021 Index also reflects on the efforts made by companies in response to COVID-19. Coronaviruses have been within the disease scope of the Access to Medicine Index since 2017. The new Index explores companies' different responses to the COVID-19 pandemic, including case studies in, for example, medicines and vaccines R&D, efforts to pool and/or scale up manufacturing capacities, fair pricing actions, licenses to enable generic versions to enter the market, emergency relief donations programmes and capacity building initiatives.
How investors use the Access to Medicine Index
The Access to Medicine Index is viewed by asset managers, asset owners and analysts as one of the most credible sources of information for assessing how pharmaceutical companies strengthen their licence to operate globally and expand in international markets. 100+ investors – together managing assets of more than USD 18 trillion – have endorsed the Index by signing the Access to Medicine Index Investor Statement, committing to using the Index in their investment analysis and engagements with companies, and gaining direct access to our analysts and resources.